5 
1 public interest it has attracted. In calling for this 
2 hearing. Secretary Califano specifically asked that we 
3 seek comments on several issues, particularly the sec- 
4 tions of the proposed revised guidelines that establish 
5 the mechanism for administering and revising the 
6 guidelines, including the procedures that would allow 
7 for otherwise prohibited experiments and the procedures 
g for exempting certain classes of research from the 
g guidelines completely. 
10 In addition, he asks that we look at the 
11 standards for the exercise of administrative discretion 
1 
12 under the guidelines by the Director of NIH, and for 
13 the composition of the various public and scientific 
14 and advisory bodies that are mentioned in the guidelines, 
15 particularly the Recombinant DNA Advisory Committee, and 
16 the institutional biosafety committees at the local 
17 level. 
10 So that is the general area of our interest, 
ig However, we will be glad to hear comments from anyone 
20 on any aspect of the revised guidelines. We are looking 
21 at a 11 issues and all aspects as we proceed with this 
22 final review. 
23 Now, because of the number of witnesses who 
24 have asked to appear, we are asking that they limit 
25 themselves to ten minutes each. Some have submitted 
[ 97 ] 
